Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move ...

Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral drug that could ...

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...